{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 95,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Uses a two-column layout to contrast failures across two different drug programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/12",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.1,
        "y": 0.35
      },
      "kind": "list",
      "text": "Regulatory Failure: MindMed dosed patients in a Phase I study 35x higher than the FDA would allow... Clinical Design Flaws: MindMed stopped at a 7-day dosing regimen...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4376066-9b15-4a40-95db-6db009db0d3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "list",
      "text": "Regulatory Failure: MindMed embarked on a Phase IIb dose finding study for MM-120 which was unnecessary... Clinical Design Flaws: The Phase IIb only tests a one dose regimen...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe7e658b-71be-4f20-8ff7-bc22d4608820",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Botched Regulatory Strategy of MM-110 Resulting in Program's Termination",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51894196-73ad-4e3b-857a-dba0f7431509",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Flawed Strategy for Core Drug MM-120",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e11a7162-d4aa-47dc-b670-ce42fe6b2be6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Company SEC Filings, MindMed Press Releases, Clinicaltrails.gov. See [3], [4]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bc96532-da3a-4ba0-988e-9567705faa24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "The Irrefutable Need For Change",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96118d2f-f5ac-495e-ad4d-75dc5cc8119d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "85b7cc19-6bf1-4224-9106-c9aec7c4aad5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the company's severe market underperformance and flawed approach to clinical development as key problems.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "736778a8-67e9-479d-853c-8d29821dfcab",
      "evidence": "The document highlights the company's severe market underperformance and the need for change.",
      "position": 0,
      "objective": "What is the cost of inaction for Mind Medicine's shareholders?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}